The impact of additive EPA or ezetimibe to statin therapy on the stabilization of vulnerable plaque; Assessment by OCT
Not Applicable
- Conditions
- Ischemic heart disease
- Registration Number
- JPRN-UMIN000011934
- Lead Sponsor
- Kobe University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded from the study if they (1) were already using statins or other lipid-lowering therapies, (2) had known hypersensitivity to statins or contrast, (3) had end-stage renal failure (serum creatinine [Cre] ≥ 2.0 mg/dL), (4) demonstrated hemodynamic and respiratory instability (e.g., cardiogenic shock, severe congestive heart failure), or (5) had no consent to participate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method